ライフサイエンスコーパス: tyrosine kinase receptor

1 t, through inhibition of the oncogenic c-Met tyrosine kinase receptor.

2 Hgf activation and signaling through its Met tyrosine kinase receptor.

3 rs when the brassinosteroids bind a membrane tyrosine kinase receptor.

4 aling through the full-length TrkB (TrkB.FL) tyrosine kinase receptor.

5 different extracellular regions of the HER-2 tyrosine kinase receptor.

6 ll proliferation and mitogenesis through its tyrosine kinase receptor.

7 the stimulation of a G(q)-protein-coupled or tyrosine-kinase receptor.

8 cycle alterations and activation of upstream tyrosine kinase receptors.

9 mall molecules, and RNA-based therapies) for tyrosine kinase receptors.

10 om epidermal growth factor receptor and HER2 tyrosine kinase receptors.

11 amined changes in miRNA that are mediated by tyrosine kinase receptors.

12 y cell surface receptors including the EphB2 tyrosine kinase receptors.

13 , we used an antibody array against multiple tyrosine kinase receptors.

14 ling by both G-protein-coupled receptors and tyrosine kinase receptors.

15 orin would modulate the bioactivity of other tyrosine kinase receptors.

16 ecule associated with multiple transmembrane tyrosine kinase receptors.

17 in receptor (p75(NTR)) or the more selective tyrosine kinase receptors.

18 he presence and intratumoral distribution of tyrosine kinase receptors.

19 responses are mediated by the ErbB family of tyrosine kinase receptors.

20 its effects on neurons by signalling through tyrosine kinase receptors.

21 s) that are not secreted and do not activate tyrosine kinase receptors.

22 a ligand-independent mechanism of activating tyrosine kinase receptors.

23 urs, where it targets either the KIT or PDGF tyrosine kinase receptors.

24 r the FGF receptor (FGFR), both of which are tyrosine kinase receptors.

25 ins overcome inhibition by MAG by activating tyrosine kinase receptors.

26 rovide new insights into the cell biology of tyrosine kinase receptors.

27 nervous system, via signalling through ErbB tyrosine kinase receptors.

28 ariety of cell surface G-protein coupled and tyrosine kinase receptors.

29 A (ShcA) is an adaptor protein that binds to tyrosine kinase receptors.

30 GFR-3 signaling but also downstream of other tyrosine kinase receptors.

31 Tyrosine kinase receptor 1 (Tie-1), collagen type IV alp

32 by soluble VEGF receptor 1/soluble Fms-like tyrosine kinase receptor 1 and soluble endoglin, a TGF-b

33 2) and VEGF signalling with soluble Fms-like tyrosine kinase receptor-1 (sFlt1).

34 f brain natriuretic factor, soluble fms-like tyrosine kinase receptor-1, troponin I, and creatinine w

35 B-type natriuretic peptide, soluble fms-like tyrosine kinase receptor-1, troponin I, soluble toll-lik

36 cross-activation between beta3 integrin and tyrosine kinase receptor 2 for vascular endothelial grow

37 Delivery of tyrosine kinase receptor-2 promoter-driven Cre to stanni

38 and used ultrasound microbubbles to deliver tyrosine kinase receptor-2 promoter-driven Cre to the ki

39 ed no Cre protein expression in cultured and tyrosine kinase receptor-2 promoter-driven Cre-transfect

40 Neurotrophic tyrosine kinase receptor 3 (TrkC) is expressed in podocy

41 Fms-like tyrosine kinase receptor 3-ligand (Flt3-L) and GM-CSF ca

42 pecific DC subsets-using GM-CSF and fms-like tyrosine kinase receptor 3-ligand (Flt3-L)-on the suscep

43 Activating mutations in FMS-like tyrosine kinase receptor-3 (FLT3) and Nucleophosmin-1 (N

44 nked to the extracellular domain of Fms-like tyrosine kinase receptor-3 ligand (FLex; a DC growth fac

45 We conclude that fms-like tyrosine kinase receptor-3 signaling is required for the

46 ignal through the cytokine receptor fms-like tyrosine kinase receptor-3 was required for the generati

47 d in part by regulatory T cells and fms-like tyrosine kinase receptor-3.

48 d protein 43, nerve growth factor (NGF), and tyrosine kinase receptor A (NTRK1) by immunohistochemist

49 or and of the nerve growth factor receptors, tyrosine kinase receptor A and p75/NGFR, irrespective of

50 caffold protein is a key mediator of the MET-tyrosine kinase receptor activated by hepatocyte growth

51 al role in modulating growth factor mediated tyrosine kinase receptor activation in early embryonic l

52 Since tyrosine kinase receptor activation is frequently associ

53 amic process in which growth factor mediated tyrosine kinase receptor activation is required, but mus

54 complex interactions that are independent of tyrosine kinase receptor activation.

55 This led us to speculate that tyrosine kinase receptor activity might be a driving for

56 Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 were identifi

57 her platelet-derived growth factor (PDGF), a tyrosine kinase receptor agonist, might transactivate an

58 (Rho- and Rho-associated kinase-dependent), tyrosine kinase receptor agonists (phosphatidylinositol

59 The tyrosine kinase receptor anaplastic lymphoma kinase (ALK

60 These findings show cross-talk between a tyrosine kinase receptor and an integrin involved in car

61 principle that vertical inhibition of both a tyrosine kinase receptor and its ligand can be therapeut

62 The Met tyrosine kinase receptor and its ligand, hepatocyte grow

63 ions as a ligand for two receptors, the TrkA tyrosine kinase receptor and the p75 neurotrophin recept

64 essed in this cancer type, including the MET tyrosine kinase receptor and the transcription factor PA

65 TrkC is a classic tyrosine kinase receptor and therefore generally conside

66 negative-feedback regulator of the EGFR/ERBB tyrosine kinase receptors and a stem cell marker.

67 diators of mitogenic and motile signaling by tyrosine kinase receptors and have been implicated in br

68 Tyrosine kinase receptors and integrins play essential r

69 am of multiple critical tumorigenic receptor tyrosine kinase receptors and oncogenic regulators, incl

70 guanine nucleotide exchange factor coupling tyrosine kinase receptors and Rac GTPases, and has been

71 findings suggest that activation of MAPKs by tyrosine kinase receptors and Ras signaling pathways may

72 otrophins are generated by activation of Trk tyrosine kinase receptors and that their death-promoting

73 umber of sequence variants in genes from the tyrosine kinase receptors and their associated pathways

74 During development, Eph tyrosine kinase receptors and their ephrin ligands funct

75 The Eph tyrosine kinase receptors and their ligands, ephrins, ar

76 The Eph family of tyrosine kinase receptors and their ligands, the ephrins

77 ed in the developing skin, activate the trkB tyrosine kinase receptor, and influence the development

78 protein associated with dephosphorylation of tyrosine kinase receptors, and prevented decline in leve

79 esponses are functionally linked to c-Src or tyrosine kinase receptors, and the physiological impact

80 Members of the ErbB family of cell surface tyrosine kinase receptors are important targets for canc

81 Hypothalamic astroglial erbB tyrosine kinase receptors are required for the timely in

82 ing mutations of genes coding for RET or TRK tyrosine kinase receptors, as well as of RAS genes.

83 gly, the ephrin type B receptor 2 (EphB2), a tyrosine kinase receptor associated with synaptic develo

84 l of CD1c(+) DC activation via regulation of tyrosine kinase receptor AXL, an important inhibitory DC

85 ersistent mTOR activation is mediated by the tyrosine kinase receptor AXL.

86 d a shift in the balance between full-length tyrosine kinase receptor B (trkB) and a truncated form o

87 Strong genetic data link the Tyrosine kinase receptor B (TrkB) and its major endogeno

88 Tyrosine kinase receptor B (TrkB) mediates neurotrophic

89 phic factor (BDNF), a cognate ligand for the tyrosine kinase receptor B (TrkB) receptor, mediates neu

90 -calmodulin-dependent kinase II (CaMKII) and tyrosine kinase receptor B (TrkB) receptors.

91 investigated the subcellular localization of tyrosine kinase receptor B (TrkB) relative to synaptic v

92 Here, we show that supraspinal BDNF-tyrosine kinase receptor B (TrkB) signaling contributes

93 ons between BDNF and its principal receptor, tyrosine kinase receptor B (TrkB), in the amygdala after

94 neurotrophic factor (BDNF) and its receptor, tyrosine kinase receptor B (TrkB), in the extended amygd

95 neurotrophic factor (BDNF) and its receptor, tyrosine kinase receptor B (TrkB), play a critical role

96 effects of T3 observed were not abolished by tyrosine kinase receptor B (TrkB)-IgG, TrkC-IgG, or K252

97 erebroventricular infusion of Fc fragment of tyrosine kinase receptor B protein (TrkB-Fc) chimera, an

98 y blocking brain-derived neurotrophic factor/tyrosine kinase receptor B signaling.

99 We report here that trkB (tyrosine kinase receptor B) is Z-linked in zebra finches

100 M can stimulate the phosphorylation of TrkB (tyrosine kinase receptor B).

101 accessory co-receptors serving to facilitate tyrosine kinase receptor binding.

102 SCF, and imatininib which blocks downstream tyrosine kinase receptors, both inhibited lung fibroblas

103 Ts16 neurons have normal levels of the TrkB tyrosine kinase receptor but an upregulation of the TrkB

104 Rin1 co-immunoprecipitated with a number of tyrosine kinase receptors but not with cargo endocytic r

105 l epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, but the role of EGFR in viral

106 urite extension after activation of the TrkA tyrosine kinase receptor by nerve growth factor (NGF) in

107 ge colony-stimulating factor (M-CSF) and the tyrosine kinase receptor c-FMS play a key role in the im

108 s signals downstream of the major melanocyte tyrosine kinase receptor c-kit and activated NRas result

109 Kit ligand (KitL) and its tyrosine kinase receptor c-kit are critical for germ cel

110 factor (HGF; decreased 60% at 16 hours) and tyrosine kinase receptor c-Met (decreased 44%-50% at 16

111 or/hepatocyte growth factor (SF/HGF) and its tyrosine kinase receptor c-Met in these tumors has been

112 On the basis of the evidence that the RON tyrosine kinase receptor can also be overexpressed in NS

113 Other growth factors that activate tyrosine kinase receptors can substitute for EGF.

114 basic helix-loop-helix family, and c-Kit, a tyrosine kinase receptor, control hematopoietic stem cel

115 eceptor complex comprised of a transmembrane tyrosine kinase receptor (cRET) and a specific glycosylp

116 Thus, by antagonistically targeting multiple tyrosine kinase receptors, decorin contributes to reduct

117 ch as neurotrophic factors and their cognate tyrosine kinase receptors (e.g., TrkB), are credible can

118 The tyrosine kinase receptor EGFR is expressed in Schwann ce

119 E4-ORF1 usurps the functions of the cellular tyrosine kinase receptors EGFR and InsR /: IGF1R, as wel

120 The ErbB/HER family comprises four distinct tyrosine kinase receptors, EGFR/ErbB1/HER1, ErbB2/HER2,

121 New findings suggest that tyrosine kinase receptor engagement results in the assem

122 neurotrophin-3 (NT3) acting through the TrkC tyrosine kinase receptor enhances migration of premyelin

123 IC1 in the transcriptional regulation of the tyrosine kinase receptor EphA2, whose ligand ephrin-A1 i

124 decreased mRNA and protein expression of the tyrosine kinase receptor EphA2.

125 oncogenic transcription factor Twist and the tyrosine kinase receptor EphA4 were expressed in total R

126 The tyrosine kinase receptor EphB4 is frequently overexpress

127 1 to forward signal through its cognate EphB tyrosine kinase receptors, ephrin-B1 can also act as a r

128 itinib-induced activation of HIF-1alpha, Met tyrosine kinase receptor, epithelial-mesenchymal transit

129 nteracts with the calcium pump PMCA2 and the tyrosine kinase receptor ErbB2/HER2 in normal mammary ep

130 re we show that the in vivo induction of the tyrosine kinase receptor, ErbB2, in mature astrocytes en

131 ants of Neuregulin 1 (NRG1) and its neuronal tyrosine kinase receptor ErbB4 are associated with risk

132 In the cerebral cortex, the tyrosine kinase receptor ErbB4 is critical for the wirin

133 Neuregulin-1 (NRG1) signaling through its tyrosine kinase receptor ErbB4 is essential for the norm

134 Here we found that the tyrosine kinase receptor ErbB4 was required for the norm

135 the growth factor neuregulin1 (NRG1) and its tyrosine kinase receptor, ErbB4.

136 etween the atypical cadherin FAT4 and RET, a tyrosine kinase receptor essential for kidney developmen

137 ulating factor 1 receptor (CSF1R) which is a tyrosine kinase receptor essential for microglia develop

138 novo gain-of-function variants in PDGFRB, a tyrosine kinase receptor essential for vascular progenit

139 EphB4 is an oncogenic tyrosine kinase receptor expressed in malignant mesothel

140 TrkB, a member of the tyrosine kinase receptor family, and its ligand, brain-d

141 and a member of the class III transmembrane tyrosine kinase receptor family.

142 receptor (TNFR) superfamily and the receptor tyrosine kinase receptor family.

143 In contrast, the tyrosine kinase receptor FGF receptor-3 (FGFR3) and the

144 ant increase in PTP activity associated with tyrosine kinase receptors FGFR-1 and KDR.

145 tion of 3 likely activating mutations in the tyrosine kinase receptor FGFR2, analogous to those repor

146 tinct subsets based on the expression of the tyrosine kinase receptor, Flk2.

147 tors (ETPs) in the thymus that expressed the tyrosine kinase receptor Flt3 and had preserved B lineag

148 Neuropilin-1 (NRP1) is a coreceptor to a tyrosine kinase receptor for both the vascular endotheli

149 It is concluded that TrkA serves as a tyrosine kinase receptor for CTGF.

150 Here, we report that c-Met, the tyrosine kinase receptor for hepatocyte growth factor (H

151 Met, the transmembrane tyrosine kinase receptor for hepatocyte growth factor (H

152 RON (recepteur d'origine nantais), a tyrosine kinase receptor for macrophage-stimulating prot

153 d erbb2, which together encode a heteromeric tyrosine kinase receptor for Neuregulin ligands.

154 c-kit, the transmembrane tyrosine kinase receptor for stem cell factor, is requir

155 The protooncogene c-met encodes the tyrosine kinase receptor for the hepatocyte growth facto

156 Overexpression of c-Met, the protein tyrosine kinase receptor for the hepatocyte growth facto

157 an also abolish the activation of Akt by the tyrosine kinase receptors for epidermal growth factor an

158 le expressing high levels of Axl, one of the tyrosine kinase receptors for growth arrest specific 6 (

159 Neuropilin-2 (NRP2) is a non-tyrosine kinase receptor frequently overexpressed in var

160 s identify a novel nuclear mechanism linking tyrosine kinase receptor function with the regulation of

161 c-Kit tyrosine kinase receptor has been identified as a regula

162 Tyrosine kinase receptors have an essential role in vari

163 in stability and subcellular localization of tyrosine kinase receptors, hence affecting signaling bot

164 e tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition r

165 HER2 (ErbB2), a member of the HER family of tyrosine kinase receptors (HER1-4), is a major driver of

166 ER2, a constitutively active fragment of the tyrosine kinase receptor HER2, results in either increas

167 interaction between Beclin-1 and the protein tyrosine kinase receptor Her2.

168 We hypothesized that the tyrosine kinase receptor human epidermal growth factor r

169 We also detected tyrosine kinase receptor immunoreactivity only in cells

170 y, inactivation of the autism-associated Met tyrosine kinase receptor in GABAergic interneurons led t

171 eptor (EGFR) family, encodes a transmembrane tyrosine kinase receptor in Her-2-positive tumors.

172 FGFs are mediated through membrane-spanning tyrosine kinase receptors in conjunction with low affini

173 Signaling through the ErbB family of tyrosine kinase receptors in normal and cancer-derived c

174 ers of the epidermal growth factor family of tyrosine kinase receptors including erbB2 that is overex

175 are over-represented in serine/threonine and tyrosine kinase receptors, including ACVR1, ACVR2B, PDGF

176 have specific activity in inhibiting select tyrosine kinase receptors, including PDGF and c-Kit.

177 rmal growth factor receptor (EGFR) and other tyrosine kinase receptors, including receptor dephosphor

178 pre-treatment with K252a, an antagonist for tyrosine kinase receptors, indicating that BDNF is actin

179 owth factor-like ligand LIN-3 and the LET-23 tyrosine kinase receptor induces ovulatory contractions

180 RNAi) to interfere with BDNF expression, and tyrosine kinase receptor inhibition to block BDNF signal

181 Intrathecal administration of the tyrosine kinase receptor inhibitor K252a and the mitogen

182 usually ineffective, but novel drugs such as tyrosine kinase receptor inhibitors show promising resul

183 viously shown that Wnt5A and ROR2, an orphan tyrosine kinase receptor, interact to mediate melanoma c

184 tivation of the KIT protein, a transmembrane tyrosine kinase receptor involved in cell survival, deve

185 We showed previously that PTK7, a tyrosine kinase receptor involved in planar cell polarit

186 an epidermal growth factor receptor 2 (HER2) tyrosine kinase receptor is overexpressed in approximate

187 Here we show that transactivation of protein-tyrosine kinase receptors is mediated by matrix metallop

188 Recepteur d' origine nantais (RON), a tyrosine kinase receptor, is aberrantly expressed in hum

189 Neuropilin-1 (NRP1), a non-tyrosine kinase receptor, is overexpressed in many cance

190 growth factor receptor alpha (PDGFRalpha), a tyrosine kinase receptor, is up-regulated in hepatic ste

191 The RET proto-oncogene, a tyrosine kinase receptor, is widely known for its essent

192 methylsphingosine), but not by inhibitors of tyrosine kinase receptors (K252a or AG879).

193 of the IL-10R JAK1 (Janus kinase) and TYK2 (tyrosine kinase) receptor kinases and tyrosine phosphory

194 Furthermore, mice with mutations in the tyrosine kinase receptor Kit lacked cardiac melanocyte-l

195 Crosses into tyrosine kinase receptor Kit(Wv) mutants indicate that E

196 iding KIT ligand, the cognate ligand for the tyrosine kinase receptor KIT.

197 Activating mutations in codon D816 of the tyrosine kinase receptor, KIT, are found in the majority

198 Mertk (TAM) represent a family of homologous tyrosine kinase receptors known for their functional rol

199 how that forward signaling through the EphA4 tyrosine kinase receptor, mediated by ephrins expressed

200 low cytometry and POS receptor proteins (Mer tyrosine kinase receptor [MerTK] and integrin subunits a

201 upon them as cofactors for activation of the tyrosine kinase receptor Met.

202 Muscle-specific tyrosine kinase receptor (MuSK) has been believed to be

203 rement of NGF for the activation of the TrkA tyrosine kinase receptor neuronal survival pathway.

204 ing amyloid precursor protein, EphB and ErbB tyrosine kinase receptors, Notch1 receptors, and adhesio

205 epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family that is abno

206 t of a 41-nucleotide sequence that targets a tyrosine kinase receptor on Jurkat T cells.

207 direct relationship between activation of a tyrosine kinase receptor oncogene and regulation of PGE2

208 hippocampal neurons using a photoactivatable tyrosine kinase receptor (optoFGFR1).

209 mutation, daf-2(e1370), in the insulin-like tyrosine kinase receptor or by over-expression of the DA

210 PDGF-C is a ligand for the tyrosine kinase receptor PDGFRalpha.

211 let-derived growth factors (PDGFs) and their tyrosine kinase receptors (PDGFRs) are known to play imp

212 f Fgfr2b and provide the first evidence of a tyrosine kinase receptor playing a tumor suppressive rol

213 sion of recepteur d'origine nantais (RON), a tyrosine kinase receptor-positive MDA-MB-231, MDA-MB-468

214 Furthermore, the transport of kinesin-1 and tyrosine kinase receptors, previously reported to requir

215 We have investigated the role of the Trk tyrosine kinase receptors, primarily TrkB, in this proce

216 The MET proto-oncogene (MET) tyrosine kinase receptor promotes many of these cellular

217 cancer producing elevated levels of the RON tyrosine kinase receptor protein.

218 7 can be activated by stimulation of several tyrosine kinase receptors, raising questions about wheth

219 te growth factor signaling downstream of the tyrosine kinase receptor remain to be determined.

220 Tyrosine kinase receptors represent targets of great int

221 TrkA is a tyrosine kinase receptor required for development and su

222 Among the SRY targets, the tyrosine kinase receptor RET represents the most importa

223 T-SP1, MSP-1, and the previously shown MSP-1 tyrosine kinase receptor RON are required for peritoneal

224 The tyrosine kinase receptor Ron has been implicated in seve

225 The gene for tyrosine-kinase receptor Ron (MST1R) resides in the chro

226 the depletion of wnt5b, vangl2 and the Wnt5b tyrosine kinase receptor ror2.

227 heral sensory neurons, where it recruits the tyrosine kinase receptors Ror2 and Ryk to modulate dendr

228 the first time, the importance of the orphan tyrosine kinase receptor, ROR2, in melanoma progression.

229 h factor A (VEGFA) and the type III receptor tyrosine kinase receptors (RTKs) are both required for t

230 Here we addressed the involvement of tyrosine kinase receptors (RTKs) in TF/FVIIa signaling b

231 C was associated with feedback activation of tyrosine kinase receptors (RTKs), AKT, mTOR, and MYC.

232 ion causes an impaired maturation of several tyrosine kinase receptors (RTKs), consistent with a part

233 ental growth factor (PlGF), soluble fms-like tyrosine kinase receptor (sFlt)-1, and galectin (gal)-3.

234 in receptor 2 (DDR2) is a collagen-activated tyrosine kinase receptor shown to be essential for skele

235 Inappropriate MET tyrosine kinase receptor signaling is detected in almost

236 we evaluated CRKL interaction with multiple tyrosine kinase receptor signaling pathways in RMS cells

237 KSHV binding activates the integrin tyrosine kinase receptor signaling pathways, leading to

238 and coupling of beta1-integrin, Notch1, and tyrosine kinase receptor signaling pathways.

239 SPROUTY-2 (SPRY2) is a modulator of tyrosine kinase receptor signaling with receptor- and ce

240 on of dominant negative Akt, an inhibitor of tyrosine kinase receptor signaling, augmented cardiomyoc

241 lecules in response to G protein-coupled and tyrosine kinase receptor signalling.

242 ties of octreotide and the overexpression of tyrosine kinase receptors such as c-kit, epidermal growt

243 ling molecule that modulates the activity of tyrosine kinase receptors such as the epidermal growth f

244 d hormone receptor, as well as growth factor tyrosine kinase receptors such as the platelet-derived g

245 ignaling, and the transactivation of protein-tyrosine kinase receptors such as those for EGF and PDGF

246 Other tyrosine kinase receptors, such as EGF and FGF receptors

247 ession of EPHA2 (Ephrin-receptor Type-A2), a tyrosine kinase receptor that has been shown to be impor

248 and constitutively active isoform of the RON tyrosine kinase receptor that has transforming activity

249 a mesenchymally produced ligand for the Ret tyrosine kinase receptor that is crucial for normal uret

250 telet-derived growth factor receptor-beta, a tyrosine kinase receptor that is required for pericyte c

251 hepatocyte growth factors) are cell-surface tyrosine kinase receptors that have been implicated in d

252 or-I (IGF-I) receptors are highly homologous tyrosine kinase receptors that share many common steps i

253 Although the insulin receptor (IR) is a tyrosine kinase receptor, the IR also couples to G-prote

254 cerol via their C1 domain upon activation of tyrosine kinase receptors, thereby restricting the magni

255 ogical effects by binding to the EC-specific tyrosine kinase receptor Tie-2, and initiates intracellu

256 ng-1 activates the endothelial cell-specific tyrosine kinase receptor Tie-2, which in turn leads to e

257 Activating mutations in the endothelial cell tyrosine kinase receptor TIE2 are a common cause of thes

258 Gain-of-function mutations in the tyrosine kinase receptor TIE2 can cause VM and induce a

259 Mechanistically, the tyrosine kinase receptor Tie2 physically interacted with

260 d that, upon irradiation, the membrane-bound tyrosine kinase receptor TIE2 translocates into the nucl

261 vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angioge

262 y of growth factors that are ligands for the tyrosine kinase receptor, Tie2.

263 eceptor agonist, might transactivate another tyrosine kinase receptor to induce SMC proliferation.

264 PI3K); and (c) association with Rho GTPases, tyrosine kinase receptors, Toll-like receptors, which re

265 Our findings suggest a new role for GIT1 in tyrosine kinase receptor trafficking.

266 neuritogenic effects were not blocked by the tyrosine kinase receptor (Trk) inhibitor K252a demonstra

267 t-derived growth factor (PDGF), neurotrophic tyrosine kinase receptor (TRK), vascular endothelial gro

268 rons are unique in the brain, expressing the tyrosine kinase receptor TrkA, together with the common

269 to detect expression in airway cells of the tyrosine kinase receptor TrkA, which binds nerve growth

270 (TRK fusions), which encode the neurotrophin tyrosine kinase receptors TRKA, TRKB, and TRKC, can resu

271 increased expression and phosphorylation of tyrosine kinase receptor (TrkA, TrkB) in lumbosacral DRG

272 t through the activation of the neurotrophic tyrosine kinase receptor TRKB.

273 n-derived neurotrophic factor (BDNF) and its tyrosine kinase receptor, TrkB, we sought to evaluate th

274 ve examined the expression and regulation of tyrosine kinase receptors (Trks) in micturition reflexes

275 tor (NGF) and activation of the neurotrophic tyrosine kinase receptor type 1 (TrkA) pathway following

276 GF increased phosphorylation of neurotrophic tyrosine kinase receptor type 1 (TrkA) receptor by ERK1

277 or (BDNF) gene and its receptor neurotrophic tyrosine kinase receptor type 2 (NTRK2) have been implic

278 iation in the expression of the neurotrophin tyrosine kinase receptor type 3 (NTRK3) in both PAND pat

279 actor ETS variant 6 (ETV6) with neurotrophic tyrosine kinase receptor, type 3 (NTRK3) and fusion of a

280 2, rs5996074, P = 9.43E-07) and neurotrophic tyrosine kinase, receptor, type 2 [NTRK2, a brain-derive

281 ad decreased mRNA expression of neurotrophic tyrosine kinase, receptor, type 3 (NTRK3).

282 The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known

283 The tyrosine kinase receptors Tyro3, Axl, and Mer (TAMs) and

284 agulant function, acts as an agonist for the tyrosine kinase receptors Tyro3, Axl, and Mer.

285 A receptor tyrosine kinase, receptor tyrosine kinase-like orphan re

286 owth factor receptor alpha (PDGFRalpha) is a tyrosine kinase receptor up-regulated and activated in s

287 d retinal changes in TrkB, the high affinity tyrosine kinase receptor used by BDNF.

288 ely active Recepteur d'Origine Nantais (RON) tyrosine kinase receptor variant that promotes migration

289 th factor-A (VEGF-A) and its 2 transmembrane tyrosine-kinase receptors, VEGFR-1 and VEGFR-2, constitu

290 divergence in DAG signaling downstream of a tyrosine-kinase receptor via a PKC-independent mechanism

291 ion prevalence in the ephrin (EPH) family of tyrosine kinase receptors was 10-fold higher in primary

292 rowth factor receptor alpha (PDGFR-alpha), a tyrosine kinase receptor, was found in previous studies

293 nvolved in signal transduction from multiple tyrosine kinase receptors, we evaluated CRKL interaction

294 main receptor 1 (DDR1) is a widely expressed tyrosine kinase receptor which binds to and gets activat

295 The proto-oncogene KIT encodes for a tyrosine kinase receptor, which is a clinically validate

296 The Met gene encodes a tyrosine kinase receptor, which is activated by Hgf (hep

297 Both FGF2 and PDGF-BB signal through tyrosine kinase receptors, which have been the target of

298 actor receptor (EGFR), a large transmembrane tyrosine kinase receptor with heterogeneous phosphorylat

299 nents, protein tyrosine kinase 7 (PTK7) is a tyrosine kinase receptor with poorly defined functions l

300 domain receptor 1, belongs to a subfamily of tyrosine kinase receptors with an extracellular domain h